KREBSBIO vs SANOFI: Stock Comparison

Krebs Biochemicals and Industries Limited vs Sanofi India Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Sanofi India Limited is the larger company by market capitalisation. Krebs Biochemicals and Industries Limited shows faster revenue growth, while Sanofi India Limited shows a higher dividend yield, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Krebs Biochemicals and Industries Limited and Sanofi India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KREBSBIO is more favourable on 4 of 11 scored metrics and SANOFI on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SANOFI is the larger company
₹7,850 Cr vs ₹117 Cr
EPS
SANOFI has higher earnings per share
₹134.59 vs ₹-7.85
Dividend Yield
SANOFI has a higher dividend yield
7.15% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs -11.9%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -14.1%
Qtr Sales Growth
KREBSBIO has stronger quarterly sales growth
11.6% vs 9.74%
Qtr Profit Growth
KREBSBIO has stronger quarterly profit growth
71.7% vs 22.4%
ROCE
SANOFI has a higher ROCE
49.2% vs -15.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOSANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOSANOFI
Live Price₹53.41₹3,412.1
Day Change-3.03%0.85%
Volume1,99713,159
52-Week High₹82.49₹5,955
52-Week Low₹38.33₹3,054
Distance from 52W High-35.25%-42.7%

Valuation

MetricKREBSBIOSANOFI
Market Cap₹117 Cr₹7,850 Cr
P/E Ratio0x0x
P/B Ratio0x0x
EPS₹-7.85₹134.59
Book Value₹-75.5₹325.31
Dividend Yield0%7.15%

Growth

MetricKREBSBIOSANOFI
Revenue Growth (TTM YoY)11.6%-11.9%
EPS Growth (TTM YoY)0%-14.1%
Qtr Sales Growth11.6%9.74%
Qtr Profit Growth71.7%22.4%

Profitability & Leverage

MetricKREBSBIOSANOFI
ROE47.1%
ROCE-15.4%49.2%
Net Margin-71.35%19.26%
Operating Margin-23%24.4%
Debt to Equity0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKREBSBIOSANOFI
Promoter Holding72.74%0%
FII Holding0.5%5.64% 0.09 pp
DII Holding0%21.13% 0.18 pp
Public Holding26.76%12.83% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Krebs Biochemicals and Industries Limited and Sanofi India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.